TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 14503833

Group type: EXPERIMENTAL
Intervention: Crown-down technique with 0.06 ProFiles series 29 to size 6 (Group 1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Step-back technique with 0.06 ProFiles series 29 to size 6 (Group 2)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Crown-down technique with Greater Taper files (GT files) (Group 3)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Step-back technique with Greater Taper files (GT files) (Group 4)
Number of subjects: 60
Study: 10915748

Group type: COMPARATOR
Intervention: Lamivudine 150 mg/d orally for 12 weeks
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Lamivudine 150 mg/d plus famciclovir 500 mg 3 times a day orally for 12 weeks
Number of subjects: 21
Study: 8831468

Group type: EXPERIMENTAL
Intervention: Methylphenidate administered twice daily at a dose of .30 mg/kg
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo administered according to the same schedule in identical pill form
Number of subjects: 23
Study: 1472662

Group type: EXPERIMENTAL
Intervention: DDAVP (0.3 micrograms/kg), IV, after cardiopulmonary bypass (CPB) and 12 hours later in the ICU
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: DDAVP (0.3 micrograms/kg), IV, after termination of CPB and saline (placebo) 12 hours later in the ICU
Number of subjects: 70

Group type: COMPARATOR
Intervention: Saline (placebo) IV after CPB and 12 hours later in the ICU
Number of subjects: 70
Study: 6585285

Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 (0.5 mg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 (1.0 mg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 (2.0 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 31184016

Group type: EXPERIMENTAL
Intervention: Serenoa repens in combination with Urtica dioiccus 160/120 mg twice daily for 3 months
Number of subjects: 102

Group type: COMPARATOR
Intervention: Serenoa repens 320 mg once a day for 3 months
Number of subjects: 102
Study: 28598553

Group type: EXPERIMENTAL
Intervention: Base intervention (20-week storybook-based intervention)
Number of subjects: 6483

Group type: EXPERIMENTAL
Intervention: Enhanced version with extended professional development for educators
Number of subjects: 6483

Group type: EXPERIMENTAL
Intervention: Home-based program for parents
Number of subjects: 6483

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 6483
Study: 27174723

Group type: EXPERIMENTAL
Intervention: Higher effort at easier task difficulty (shorter PEP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diminished effort at harder task difficulty (longer PEP)
Number of subjects: 0
Study: 24394584

Group type: EXPERIMENTAL
Intervention: F‐ brush+F‐ rinse 2× per day
Number of subjects: 12

Group type: COMPARATOR
Intervention: F‐ brush+F‐ rinse once a day
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: F‐ brush+rinsing with 0.05% NaF after lunch
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: F‐ brush+F‐ rinse before bedtime
Number of subjects: 12

Group type: COMPARATOR
Intervention: F‐ brush
Number of subjects: 12
Study: 23318614

Group type: EXPERIMENTAL
Intervention: Lesser tuberosity osteotomy
Number of subjects: 86

Group type: COMPARATOR
Intervention: Subscapularis peel
Number of subjects: 86
Study: 21111309

Group type: EXPERIMENTAL
Intervention: Yellow-tinted IOLs (AF-1 (UY), AcrySof SN60AT)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Clear IOLs (AF-1 (UV), AcrySof SA60AT)
Number of subjects: 80
Study: 18490214

Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Metoclopramide 10 mg
Number of subjects: 80
Study: 15690408

Group type: EXPERIMENTAL
Intervention: CD‐ROM only
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Feedback to counselor only
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Both CD‐ROM and feedback
Number of subjects: 197

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 197
Study: 12610802

Group type: EXPERIMENTAL
Intervention: Topical Tripterygium wilfordii (TW)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 10730525

Group type: EXPERIMENTAL
Intervention: Intravenous indomethacin (0.2 mg/kg initially, then 0.1 mg/kg every 12 hours for 2 more doses)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intravenous indomethacin
Number of subjects: 30
Study: 7723643

Group type: EXPERIMENTAL
Intervention: Large fluid replacement (Large FR) - 1330 +/- 60 ml of a 6% carbohydrate solution (79 +/- 4 g)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Small fluid replacement (Small FR) - 200 +/- 10 ml of a 40% maltodextrin solution (79 +/- 4 g)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Carbohydrate ingestion (CHO) - 6% carbohydrate solution (79 +/- 4 g)
Number of subjects: 8

Group type: COMPARATOR
Intervention: No carbohydrate ingestion (NO CHO) - water
Number of subjects: 8
Study: 2119958

Group type: EXPERIMENTAL
Intervention: Intravenous tetrandrine (0.12 to 0.21 g)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Intravenous tetrandrine
Number of subjects: 27
Study: 121640

Group type: EXPERIMENTAL
Intervention: Levonorgestrel 15 microgram and ethinyloestradiol 30 microgram
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Levonorgestrel 50 microgram with ethinyloestradiol 50 microgram for 11 days, followed by levonorgestrel 125 microgram for 11 days, followed by levonorgestrel 125 microgram with ethinyloestradiol 50 microgram for 10 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 31168688

Group type: EXPERIMENTAL
Intervention: Apixaban 2.5 mg BD
Number of subjects: 10

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 10
Study: 28865915

Group type: EXPERIMENTAL
Intervention: Closed Loop Anaesthesia Delivery System (CLADS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Target Controlled Infusion (TCI)
Number of subjects: 40
Study: 26630923

Group type: EXPERIMENTAL
Intervention: Short Physical Performance Battery (SPPB) scores
Number of subjects: 48
Study: 23059865

Group type: EXPERIMENTAL
Intervention: Soccer training group (STG)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Doctor advice group (DAG)
Number of subjects: 33
Study: 21596588

Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics administered 5 minutes before exsanguination and inflation of the tourniquet (ABT)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Prophylactic antibiotics administered 1 minute after inflation of the tourniquet (AAT)
Number of subjects: 106
Study: 18302700

Group type: EXPERIMENTAL
Intervention: Almotriptan 12.5 mg
Number of subjects: 315

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 315
Study: 17196059

Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Noradrenergic and specific serotonergic antidepressant (NaSSA) mirtazapine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Tricyclic antidepressants (TCAs)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Serotonin-norepinephrine reuptake inhibitor (SNRI) venlafaxine
Number of subjects: 100
Study: 12728082

Group type: EXPERIMENTAL
Intervention: PMF formula (Enfamil with iron) containing PO/coconut/soy/high-oleic sunflower oils (45/20/20/15% oil)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Milk-based formula without PO (Similac with iron) containing high-oleic safflower/coconut/soy oils (40/30/30% oil)
Number of subjects: 128
Study: 10918548

Group type: EXPERIMENTAL
Intervention: Ambulatory blood pressure monitoring (ABPM), n = 651
Number of subjects: 1298

Group type: COMPARATOR
Intervention: Casual blood pressure measurement in the physician's practice (PM), n = 647
Number of subjects: 1298

Group type: EXPERIMENTAL
Intervention: ABPM, n = 651
Number of subjects: 1298

Group type: COMPARATOR
Intervention: PM, n = 647
Number of subjects: 1298
Study: 1426223

Group type: EXPERIMENTAL
Intervention: Sitting position
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Supine position
Number of subjects: 10
Study: 4050842

Group type: EXPERIMENTAL
Intervention: 10 mg sublingual nifedipine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 20 mg sublingual nifedipine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: sublingual nifedipine
Number of subjects: 30
Study: 31246604

Group type: EXPERIMENTAL
Intervention: Anesthetized arm
Number of subjects: 12

Group type: COMPARATOR
Intervention: Awake arm
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Female subjects
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 10-kg increase in body weight
Number of subjects: 12
Study: 29322167

Group type: EXPERIMENTAL
Intervention: High-risk plaque detected by coronary CTA
Number of subjects: 4415
Study: 26761270

Group type: EXPERIMENTAL
Intervention: Combination cognitive behavioral therapy and medication management algorithm (COMB)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 44
Study: 24834933

Group type: EXPERIMENTAL
Intervention: oVEMP test after 12 hours sleep deprivation
Number of subjects: 20

Group type: COMPARATOR
Intervention: oVEMP test after normal sleep
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: cVEMP test after 12 hours sleep deprivation
Number of subjects: 20

Group type: COMPARATOR
Intervention: cVEMP test after normal sleep
Number of subjects: 20
Study: 22538693

Group type: EXPERIMENTAL
Intervention: Cap-assisted technique
Number of subjects: 6

Group type: COMPARATOR
Intervention: Non-cap technique
Number of subjects: 6
Study: 20657612

Group type: EXPERIMENTAL
Intervention: Inhibitors of the renin-angiotensin system
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 18622895

Group type: EXPERIMENTAL
Intervention: Virgin olive oil
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Common olive oil
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Refined olive oil
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Low phenolic olive oil
Number of subjects: 38

Group type: COMPARATOR
Intervention: Medium phenolic olive oil
Number of subjects: 38

Group type: COMPARATOR
Intervention: High phenolic olive oil
Number of subjects: 38
Study: 15714903

Group type: EXPERIMENTAL
Intervention: Saccadic head movements
Number of subjects: 1
Study: 12120777

Group type: EXPERIMENTAL
Intervention: Single Bond
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PermaQuik
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: One‐Up Bond F
Number of subjects: 0
Study: 10413893

Group type: EXPERIMENTAL
Intervention: Sodium monofluorophosphate (MFP) 15 mg F/day for 18 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sodium fluoride (NaF) 30 mg F/day for 18 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sodium fluoride (NaF) 30 mg F/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sodium monofluorophosphate (MFP) 15 mg F/day
Number of subjects: 0
Study: 8543385

Group type: EXPERIMENTAL
Intervention: Dacarbazine (DTIC) and Vindesine (Eldesine) with addition of Cisplatin (Platinol)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Dacarbazine (DTIC) and Vindesine (Eldesine) without Cisplatin (Platinol)
Number of subjects: 87
Study: 1900225

Group type: EXPERIMENTAL
Intervention: urokinase-preactivated prourokinase
Number of subjects: 55

Group type: COMPARATOR
Intervention: tissue-type plasminogen activator
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: thrombin-antithrombin III complex levels greater than 6 ng/l
Number of subjects: 55
Study: 6132852

Group type: EXPERIMENTAL
Intervention: Metoclopramide, 10 mg intramuscularly
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Metoclopramide, 10 mg orally
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Bethanechol, 0.07 mg/kg subcutaneously
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control subjects (26 normal gastric emptying rate)
Number of subjects: 24
Study: 31004213

Group type: EXPERIMENTAL
Intervention: High-intensity training (HIT) for 8 weeks, followed by 8 weeks of self-training
Number of subjects: 10

Group type: COMPARATOR
Intervention: No training for 8 weeks followed by non-supervised HIT for 8 weeks
Number of subjects: 10
Study: 28257378

Group type: EXPERIMENTAL
Intervention: 0.2 μg/day fluocinolone acetonide (FAc)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 100
Study: 27281531

Group type: EXPERIMENTAL
Intervention: TEV‐48125 675/225 mg
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: TEV‐48125 900 mg
Number of subjects: 261

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 261
Study: 24614572

Group type: EXPERIMENTAL
Intervention: Remote monitoring (RM)
Number of subjects: 310

Group type: COMPARATOR
Intervention: Ambulatory follow-ups (control)
Number of subjects: 310
Study: 22840457

Group type: EXPERIMENTAL
Intervention: Combined treatment group (GBT + conventional treatment)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional treatment group (control group)
Number of subjects: 80
Study: 19815939

Group type: EXPERIMENTAL
Intervention: Wide-field digital retinal imaging (WFDRI)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Binocular indirect ophthalmoscopy (BIO)
Number of subjects: 76
Study: 17691587

Group type: EXPERIMENTAL
Intervention: Fe‐59 labeled iron(III)‐hydroxide polymaltose complex (IPC, Maltofer) equivalent to 100 mg elemental iron
Number of subjects: 22

Group type: COMPARATOR
Intervention: Fe‐59 labeled IPC complex equivalent to 100 mg elemental iron and 500 mg tetracycline HCl
Number of subjects: 22
Study: 16013427

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 12011578

Group type: EXPERIMENTAL
Intervention: Soy milk providing 25 g/day of protein
Number of subjects: 20

Group type: COMPARATOR
Intervention: Cow's milk (identically formulated)
Number of subjects: 20
Study: 10445772

Group type: EXPERIMENTAL
Intervention: Remifentanil 1 microg/kg and placebo infusion
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Remifentanil infusion (remifentanil 1 microg/kg and infusion of 0.2 microg/kg/min)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Alfentanil 7 microg/kg and placebo infusion
Number of subjects: 79
Study: 7796715

Group type: EXPERIMENTAL
Intervention: 40 mg i.v. cocaine
Number of subjects: 0
Study: 1756260

Group type: EXPERIMENTAL
Intervention: High-dose megestrol acetate (HDMA) at doses of 480, 800, 1280, and 1600 mg/d
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: High-dose megestrol acetate (HDMA)
Number of subjects: 57
Study: 7181824

Group type: EXPERIMENTAL
Intervention: White noise presented during reported hallucinations
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: White noise followed hallucinations
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control condition (white noise presented randomly)
Number of subjects: 3
Study: 31475635

Group type: EXPERIMENTAL
Intervention: Active case finding (ACF)
Number of subjects: 572

Group type: COMPARATOR
Intervention: Passive case finding (PCF)
Number of subjects: 572
Study: 28403458

Group type: EXPERIMENTAL
Intervention: Cessation intervention
Number of subjects: 207
Study: 25406967

Group type: EXPERIMENTAL
Intervention: 1.5 g/d eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) as ready‐to‐eat meals enriched with liquid fish oil
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: 1.5 g/d eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) as microencapsulated fish oil powder and regular meals
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo powder and regular meals
Number of subjects: 99
Study: 25253543

Group type: EXPERIMENTAL
Intervention: Diagnostic Apathia Scale
Number of subjects: 56
Study: 22728292

Group type: EXPERIMENTAL
Intervention: MMF 2 g/d
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: MMF 3 g/d
Number of subjects: 133

Group type: COMPARATOR
Intervention: AZA
Number of subjects: 133
Study: 19958860

Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (rHuEpo) 200 U/kg daily for 3 consecutive days
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 17325502

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 20

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 20
Study: 15077243

Group type: EXPERIMENTAL
Intervention: Electronic diary
Number of subjects: 20

Group type: COMPARATOR
Intervention: Paper diary
Number of subjects: 20
Study: 12201939

Group type: EXPERIMENTAL
Intervention: Intravesical IFN gamma (0.7 mg per week for 8 weeks)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (untreated after transurethral resection)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Intravesical IFN gamma
Number of subjects: 54
Study: 9659016

Group type: EXPERIMENTAL
Intervention: 5% sevoflurane
Number of subjects: 36

Group type: COMPARATOR
Intervention: 2.5% halothane
Number of subjects: 36
Study: 8567768

Group type: EXPERIMENTAL
Intervention: Human growth hormone (Norditropin, 12 IU/day, i.m., for 7 days)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 2653217

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin plus netilmicin
Number of subjects: 214

Group type: COMPARATOR
Intervention: Piperacillin plus netilmicin
Number of subjects: 214
Study: 305467

Group type: EXPERIMENTAL
Intervention: Cerebellar stimulation for two periods of 24 hours
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Cerebellar stimulation
Number of subjects: 11
Study: 29166767

Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine (CHX)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: boiled water
Number of subjects: 120

Group type: COMPARATOR
Intervention: normal saline
Number of subjects: 120
Study: 28257242

Group type: EXPERIMENTAL
Intervention: Peer network interventions (n=47)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Business-as-usual control group (n=48)
Number of subjects: 47
Study: 25301816

Group type: EXPERIMENTAL
Intervention: Retention strategies including flexible scheduling, convenient locations, and incentives
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: Participant demographics and health characteristics
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: History of excessive drinking and drug use
Number of subjects: 430
Study: 24060302

Group type: EXPERIMENTAL
Intervention: Simulator training group (N=35)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Cadaver eyes training group (N=30)
Number of subjects: 65
Study: 23171246

Group type: EXPERIMENTAL
Intervention: Slow eating rate
Number of subjects: 30

Group type: COMPARATOR
Intervention: Fast eating rate
Number of subjects: 30
Study: 19656359

Group type: EXPERIMENTAL
Intervention: Knowledge of stroke risk factors and warning signs
Number of subjects: 2033

Group type: COMPARATOR
Intervention: Education level
Number of subjects: 2033

Group type: COMPARATOR
Intervention: Geographic location
Number of subjects: 2033
Study: 17717235

Group type: EXPERIMENTAL
Intervention: 50 mL water
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 300 mL water
Number of subjects: 10

Group type: COMPARATOR
Intervention: Comparison of 300 mL vs 50 mL water
Number of subjects: 10
Study: 15305335

Group type: EXPERIMENTAL
Intervention: Bioavailable testosterone levels
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Estradiol/bioavailable testosterone ratio
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Estradiol levels
Number of subjects: 320
Study: 11724848

Group type: EXPERIMENTAL
Intervention: MYCO/F Lytic bottle
Number of subjects: 6108

Group type: COMPARATOR
Intervention: Isolator system
Number of subjects: 6108

Group type: EXPERIMENTAL
Intervention: BACTEC Plus Aerobic/F bottle
Number of subjects: 6108

Group type: EXPERIMENTAL
Intervention: Combination of Isolator system and MYCO/F Lytic bottle
Number of subjects: 6108
Study: 9666944

Group type: EXPERIMENTAL
Intervention: Sodium fluoride therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7980801

Group type: EXPERIMENTAL
Intervention: New treatment E
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard therapy S
Number of subjects: 0
Study: 3060193

Group type: EXPERIMENTAL
Intervention: Ketanserin 20 mg three times a day for 1 week, then 40 mg three times a day for 4 weeks
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 31128269

Group type: EXPERIMENTAL
Intervention: TeachTown: Basics (computer-assisted intervention), 20 minutes per day for 3 months
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 22
Study: 30460354

Group type: EXPERIMENTAL
Intervention: Resin-modified glass-ionomer cement (RMGIC) with fluoride toothpaste
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Glass carbomer with fluoride toothpaste
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Giomer
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no fluoride toothpaste)
Number of subjects: 60
Study: 28947468

Group type: EXPERIMENTAL
Intervention: High DHA fish oil capsules
Number of subjects: 5540

Group type: COMPARATOR
Intervention: Control capsules without DHA
Number of subjects: 5540
Study: 26373743

Group type: EXPERIMENTAL
Intervention: Probiotics (Lactobacillus acidophilus, Enterococcus faecium and Bifidobacterium infantum) at a dose of 0.6 × 107 colony‐forming units twice daily
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Probiotics (Lactobacillus acidophilus, Enterococcus faecium and Bifidobacterium infantum)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no probiotics)
Number of subjects: 80
Study: 22647247

Group type: EXPERIMENTAL
Intervention: Fish protein supplement (3 g/d for the first 4 weeks and 6 g/d for the last 4 weeks)
Number of subjects: 34
Study: 21638149

Group type: EXPERIMENTAL
Intervention: 2.0 g ginger extracts
Number of subjects: 0
Study: 19047538

Group type: COMPARATOR
Intervention: Behavioral parent-only intervention
Number of subjects: 93

Group type: COMPARATOR
Intervention: Behavioral family-based intervention
Number of subjects: 93
Study: 17137894

Group type: EXPERIMENTAL
Intervention: Antistatic valved holding chamber/mask (AeroChamber MAX)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Conventional valved holding chamber/mask (AeroChamber Plus)
Number of subjects: 12
Study: 12585986

Group type: EXPERIMENTAL
Intervention: Duct tape
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional cryotherapy
Number of subjects: 0
Study: 10861274

Group type: EXPERIMENTAL
Intervention: CT colonography (VC)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional colonoscopy (CC)
Number of subjects: 50